NRx Pharmaceuticals Shares Are Trading Lower After the Company Announced Findings From Its Phase 2b/3 Trial of NRX-101 Vs. Lurasidone.
NRx Pharmaceuticals Shares Are Trading Lower After the Company Announced Findings From Its Phase 2b/3 Trial of NRX-101 Vs. Lurasidone.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.